It would be informative to identify patients at high risk for NE/SC (e.g., those carrying TP53, RB1 and PTEN alteration or AURKA/MYCN amplification in their primary PCa or biopsies at later stages) and compare the long-term prevalence of NE/SC in BAT-treated patients versus untreated patients. Here, MYCN is linked to posterior cortical atrophy.